- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02539966
Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II)
March 27, 2023 updated by: REVA Medical, Inc.
The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
220
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jeffrey Anderson
- Phone Number: 858-966-3038
- Email: janderson@revamedical.com
Study Locations
-
-
-
Chermside, Australia
- The Prince Charles Hospital
-
Darlinghurst, Australia
- St Vincent'S Hospital Sydney
-
Randwick, Australia
- Prince of Wales Hospital (Eastern Heart)
-
-
-
-
-
Aalst, Belgium
- Cardiovascular Center Aalst
-
-
-
-
-
Sao Paulo, Brazil
- Instituto Dante Pazzanese de Cardiologia
-
São Paulo, Brazil
- Albert Einstein Hospital
-
-
-
-
-
Aarhus, Denmark
- Aarhus University Hospital (Skejby)
-
Copenhagen, Denmark
- Rigshospitalet
-
Odense, Denmark
- Odense University Hospital
-
-
-
-
-
Massy, France
- institut Hospitalier J.Cartier
-
Paris, France
- La Pitié-Salpêtrière
-
Toulouse, France
- Hopital Rangueil
-
Toulouse, France
- Clinique PASTEUR
-
-
-
-
-
Berlin, Germany
- Am Urban Hospital, Berlin
-
Berlin, Germany
- Friedrichshein Hospital, Berlin
-
Coburg, Germany
- Klinikum Coburg
-
Dortmund, Germany
- St.- Johannes-Hospital Dortmund
-
Erlangen, Germany
- Universitätsklinikum Erlangen
-
Essen, Germany
- Elisabeth-Krankenhaus Essen
-
Kiel, Germany
- Universitätsklinikum Schleswig-Holstein
-
-
-
-
-
Amsterdam, Netherlands
- Onze Lieve Vrouwe Gasthuis
-
Amsterdam, Netherlands
- Academic Medical Center Amsterdam
-
Rotterdam, Netherlands
- Erasmus Medical Center
-
Utrecht, Netherlands
- University Medical Center Utrecht
-
-
-
-
-
Krakow, Poland
- Szpital Uniwersytecki w Krakowie
-
Krakow, Poland
- Krakowskie Centrum Kardiologii Inwazyjnej
-
Poznan, Poland
- Szpital Kliniczny Przemienienia Panskiego UM w Poznaniu
-
Warszawa, Poland
- Oddział Kardiologii Inwazyjnej I Katedra
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient has evidence of myocardial ischemia or a positive functional study
- Target lesion has a visually estimated stenosis of ≥50% and <100%
- Target lesion is located in a native coronary artery with average reference vessel diameter ≥ 2.5mm and ≤ 3.5mm
- Lesion length ≤ 20 mm by visual estimate (N/A for Cohort C)
- Baseline TIMI flow ≥ 2
Exclusion Criteria:
- The patient has experienced an acute myocardial infarction (AMI: STEMI or NSTEMI) within 72 hours of the procedure and either CK-MB or Troponin has not returned to within 2X ULN.
- Patient has a left ventricular ejection fraction < 40%
- Patient has unprotected left main coronary disease with ≥50% stenosis
- The target vessel is totally occluded (TIMI Flow 0 or 1)
- Target lesion involves a bifurcation (a lesion with a side branch ≥ 1.5 mm in diameter containing a ≥ 50% stenosis).
- Target lesion is located within a bypass graft
- Target lesion has possible or definite thrombus
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)
|
Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
|
Experimental: Cohort B
Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)
|
Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
|
Experimental: Cohort C
Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel
|
Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Adverse Cardiac Events (MACE) - Cohorts A, B and C
Time Frame: 6 months
|
Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB >5X ULN) (MI), and target lesion revascularization (TLR)
|
6 months
|
Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C
Time Frame: 6 months
|
Late Lumen Loss
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantitative Coronary Angiography (QCA) derived parameters - Cohort B
Time Frame: 9 months
|
Late Lumen Loss
|
9 months
|
Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C
Time Frame: 6 months
|
Minimum Lumen Diameter (MLD)
|
6 months
|
Quantitative Coronary Angiography (QCA) derived parameters - Cohort B
Time Frame: 9 months
|
Minimum Lumen Diameter (MLD)
|
9 months
|
Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C
Time Frame: 6 months
|
% Diameter Stenosis
|
6 months
|
Quantitative Coronary Angiography (QCA) derived parameters - Cohort B
Time Frame: 9 months
|
% Diameter Stenosis
|
9 months
|
Quantitative Coronary Angiography (QCA) derived parameters - Cohorts A and C
Time Frame: 6 months
|
Binary Restenosis
|
6 months
|
Quantitative Coronary Angiography (QCA) derived parameters - Cohort B
Time Frame: 9 months
|
Binary Restenosis
|
9 months
|
Major Adverse Cardiac Events (MACE) - Cohorts A, B and C
Time Frame: 12, 24, 36, 48 and 60 months
|
Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB >5X ULN) (MI), and target lesion revascularization (TLR)
|
12, 24, 36, 48 and 60 months
|
Target Lesion Revascularization (TLR) - Cohorts A, B and C
Time Frame: 12, 24, 36, 48 and 60 months
|
Percentage of patients with TLR at each time point
|
12, 24, 36, 48 and 60 months
|
Target Vessel Revascularization (TVR) - Cohorts A, B and C
Time Frame: 12, 24, 36, 48 and 60 months
|
Percentage of patients with TVR at each time point
|
12, 24, 36, 48 and 60 months
|
Target Vessel Failure (TVF) - Cohorts A, B and C
Time Frame: 12, 24, 36, 48 and 60 months
|
Percentage of patients with TVF at each time point
|
12, 24, 36, 48 and 60 months
|
Acute Technical Success - Cohorts A, B and C
Time Frame: Day 0
|
Successful acute delivery and deployment of the device
|
Day 0
|
Procedural Success - Cohorts A, B and C
Time Frame: 30 days
|
Percentage of patients with angiographic success (final diameter stenosis <50% without occurrence of MACE)
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia
- Principal Investigator: Christoph K Naber, PD Dr. med, Elisabeth-Krankenhaus Essen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2015
Primary Completion (Actual)
August 1, 2019
Study Completion (Anticipated)
February 1, 2024
Study Registration Dates
First Submitted
September 1, 2015
First Submitted That Met QC Criteria
September 1, 2015
First Posted (Estimate)
September 3, 2015
Study Record Updates
Last Update Posted (Actual)
March 30, 2023
Last Update Submitted That Met QC Criteria
March 27, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- HCT6200
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
-
Elixir Medical CorporationCompletedCoronary Artery DiseaseNew Zealand, Belgium
-
Amaranth Medical Inc.UnknownMyocardial Ischemia | Coronary Artery DiseaseColombia, Italy
-
Elixir Medical CorporationCompletedCoronary Artery DiseaseNew Zealand, Belgium, Germany, Poland, Denmark, Brazil
-
Amaranth Medical Inc.UnknownMyocardial Ischemia | Coronary Artery DiseaseItaly, Colombia
-
Amaranth Medical Inc.UnknownMyocardial Ischemia | Coronary Artery DiseaseColombia
-
Amaranth Medical Inc.UnknownMyocardial Ischemia | Coronary Artery DiseaseItaly
-
Inova Health Care ServicesWithdrawnCoronary Artery DiseaseUnited States
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaTerminatedCoronary StenosisKorea, Republic of
-
Biotronik AGCBCC-VIBGYOR Research Pvt. Ltd.SuspendedCoronary Artery DiseaseIndia
-
Joost DaemenHorizon 2020 - European Commission; REVA Medical, Inc.RecruitingPercutaneous Coronary Intervention | Tomography, Optical Coherence | Myocardial RevascularizationNetherlands, Belgium